Alterity Therapeutics Reports Positive Phase 2 Trial Results for MSA Treatment

An update from Alterity Therapeutics Ltd. ( (AU:ATH) ) is now available.

Alterity Therapeutics announced promising results from their ATH434-201 Phase 2 clinical trial at the European MSA Symposium. The trial demonstrated that ATH434 significantly reduced disease severity in MSA patients, with improvements in daily living activities and motor performance. ATH434 was well tolerated, showing potential for further development in treating MSA, a rare neurodegenerative disorder. The study’s positive outcomes, including target engagement and brain volume preservation, support the continued advancement of ATH434, which has been granted Orphan Drug Designation by the U.S. FDA and the European Commission.

More about Alterity Therapeutics Ltd.

Alterity Therapeutics Ltd. is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases. Their primary product, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration, with potential applications in treating Parkinson’s disease and disorders like Multiple System Atrophy (MSA).

Average Trading Volume: 1,000

Technical Sentiment Signal: Buy

Current Market Cap: $46.61M

For an in-depth examination of ATH stock, go to TipRanks’ Stock Analysis page.